Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.600
+0.060 (2.36%)
At close: Nov 14, 2025, 4:00 PM EST
2.590
-0.010 (-0.38%)
After-hours: Nov 14, 2025, 7:47 PM EST
Editas Medicine Revenue
Editas Medicine had revenue of $7.54M in the quarter ending September 30, 2025, with 12,265.57% growth. This brings the company's revenue in the last twelve months to $46.38M, down -24.90% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.
Revenue (ttm)
$46.38M
Revenue Growth
-24.90%
P/S Ratio
4.77
Revenue / Employee
$188,549
Employees
246
Market Cap
253.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EDIT News
- 6 days ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 13 days ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 weeks ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 5 weeks ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 5 weeks ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 2 months ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire
- 2 months ago - Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate - GlobeNewsWire